RXRX NASDAQ
Recursion Pharmaceuticals, Inc.
1W: +10.2%
1M: +21.9%
3M: +4.0%
YTD: -1.9%
1Y: -19.2%
3Y: -47.0%
5Y: -83.2%
$4.12
+0.05 (+1.23%)
Weekly Expected Move ±12.2%
$3
$4
$4
$5
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.45
Bearish
0 bullish
1 neutral
1 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (100)
Most and least shorted mid- to mega-cap healthcare stocks at the end of September
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
Recursion Pharmaceuticals (RXRX) Stock Moves 2.02%: What You Should Know
Catalyst Watch: Trump-Xi in DC, Meta Connect, and McDonald's Investor Day
FDA Grants Priority Review to AZN's Filing for Rare Bone Disease Drug
RXRX Stock Holds Steady As Insider Form 4 Filings Stack Up - timothysykes.com
RXRX Stock Steadies As Insider Activity Draws Trader Focus - StocksToTrade
Recursion Pharmaceuticals (RXRX): Can Its AI Platform Translate Into Clinical Wins? - RTTNews
Recursion Pharmaceuticals Stock (RXRX) Opinions on Recent Conference Updates and Partnerships - Moomoo
Recursion Pharmaceuticals (RXRX) CFO’s 5,396-share move wasn’t a sale - Stock Titan
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Catalyst Watch: FOMC blockbuster, Salesforce event, and 24-hour trading talk
Is Recursion Pharmaceuticals (RXRX) Stock Fully Priced After Its 87% Fall? - simplywall.st
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today - Yahoo Finance
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
FDA names acting heads of drug and vaccine units to permanent roles
2 Beaten-Down Stocks to Avoid Right Now
2 Beaten-Down Stocks to Avoid Right Now
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 6.9% – Time to Buy?
Catalyst watch: Apple's high-stakes iPhone event, Oracle, CPI, and the NFL returns
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report? - Yahoo Finance
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook? - Yahoo Finance
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in Aug 2026
Recursion Pharmaceuticals Stock (RXRX) Opinions on AI Drug Discovery Pipeline - Quiver Quantitative
$RXRX stock fell 5% this week. Here's what we see in our data. - Quiver Quantitative
Biotech Breakout: What's in focus after Moderna's cancer win?
Recursion Pharmaceuticals Stock Climbs 13% As AI Drug Pipeline Progress And Spending Cuts Boost Sentiment - TIKR.com
Biotechs hit a post-pandemic high after mRNA trial win for Moderna, Merck
Recursion Pharmaceuticals Stock (RXRX) Opinions on Clinical Pipeline and AI Platform Developments - Quiver Quantitative
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci
Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
Recursion Pharmaceuticals (RXRX) Stock Dropped, So What Is Behind The Move? - simplywall.st
Recursion Pharmaceuticals, Inc. $RXRX Stake Increased by California State Teachers Retirement System
Recursion (RXRX) Q2 2026 Earnings Call Transcript
Recursion (RXRX) Q2 2026 Earnings Call Transcript
RXRX Q2 Earnings Miss Estimates, Revenues Fall Y/Y, Stock Down
Recursion Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Recursion Pharmaceuticals (RXRX) Is Up 11.4% After Mixed Q2 Results And Genentech Milestone Update
Recursion Pharmaceuticals (RXRX) Stock Still Looks Expensive Following August 5 Results Update
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Misses Revenue Estimates
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Misses Revenue Estimates
Recursion Pharmaceuticals (RXRX) Stock Still Looks Expensive Following August 5 Results Update - Yahoo Finance
Recursion to Participate in Upcoming Investor Conferences
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $8.10 Average Target Price from Brokerages
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
3 Stocks With the Most Upside by the End of 2026
Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider
Amova Asset Management Americas Inc. Sells 801,804 Shares of Recursion Pharmaceuticals, Inc. $RXRX
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know
Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today
Cathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy?
2 Beaten-Down Stocks That Still Aren't Worth Buying
Is Recursion Pharmaceuticals (RXRX) The Best Penny Stocks According to Billioanires? - Yahoo Finance
Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market
3 Cancer Stocks to Watch as Oncology Innovation Accelerates
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Recursion Pharmaceuticals (RXRX) Stock Looks Fully Valued Despite AI Drug Hopes - Yahoo Finance
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market
2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying
Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
Recursion Pharmaceuticals (RXRX) Stock Valuation After AI Drug Discovery And REC-1245 REC-4881 Updates - Yahoo Finance
Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue?
RXRX Stock Climbs As Earnings Beat Extends Cash Runway - timothysykes.com
Why Recursion Pharmaceuticals (RXRX) Is Up 9.5% After AI Pipeline Progress And Stronger-Than-Expected Q1 Results
Recursion’s AI Drug Pipeline Progress Tests Investor Patience And Valuation
[144] RECURSION PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?
A Look At Recursion Pharmaceuticals (RXRX) Valuation As Shares Show Short Term Momentum - simplywall.st
RXRX (NASDAQ) affiliate sales reported: Borgeson sells 230,000 shares in 2026 - Stock Titan
Recursion to Participate in Upcoming Investor Conferences
Clinical-stage TechBio Recursion to appear at Goldman Sachs healthcare event - Stock Titan
RXRX Stock Climbs As Earnings Beat And AI Pipeline Advance - timothysykes.com
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
TechBio Recursion awards 2,991,840 restricted stock units to 33 hires - Stock Titan
Why Recursion Pharmaceuticals (RXRX) Is Up 7.1% After Extending Cash Runway And Advancing REC-4881 - simplywall.st
Verge, following trial failure, rebrands its AI drug discovery ambitions
Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now?
Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now?
Recursion Pharmaceuticals (RXRX) Hits 52-Week Low; Is It In Oversold Territory?
A Look At Recursion Pharmaceuticals (RXRX) Valuation As Mixed Signals Emerge On Future Growth Prospects
Morgan Stanley Raises its Price Target on Recursion (RXRX)
Recursion Pharmaceuticals Stock (RXRX) Opinions on AI Drug Discovery Initiatives - Quiver Quantitative